Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Related News
Insights
Company Spotlight
A clinical-stage biotech company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.
Latest News & Features of interest to Merck KGaA
Pharmaceutical
Takeda today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024). 31 July 2024
Pharmaceutical
Lundbeck announced it has been agreed with Takeda Pharmaceutical to modify the current collaboration in the USA. 31 July 2024
Biotechnology
Japanese drugmaker Chugai has signed a license agreement with Swiss pharma giant Roche for inavolisib. 31 July 2024
Pharmaceutical
Swiss pharma giant Roche is wasting no time in catching up with obesity frontrunners Novo Nordisk and Eli Lilly. 31 July 2024
Pharmaceutical
The potential benefits for GLP-1 agonists appear unlimited, with new data at a leading Alzheimer’s conference suggesting a possible benefit for people taking an earlier generation option from Novo Nordisk (NOV: N). 31 July 2024
Biotechnology
Eisai (Tokyo: 4523) and Biogen (Nasdaq: BIIB) have shared new findings on Leqembi (lecanemab), the star of the show at the Alzheimer’s Association International Conference (AAIC) 2024. 31 July 2024
Biotechnology
Osaka-based Ono Pharmaceutical (TYO: 4502) has added a new collab to a growing list of deals made in 2024, agreeing to work with Systasy Bioscience. 31 July 2024
Biotechnology
MacroGenics yesterday announced the achievement of $100 million in milestones from Incyte Corp . 31 July 2024
Pharmaceutical
Shares in Merck & Co were more than 10% lower during Tuesday’s early trading in New York after the US pharma giant announced its second-quarter financial results and latest guidance for 2024. 30 July 2024
Biotechnology
Imunon has released data from the Phase II OVATION 2 study of its interleukin-12 (IL-12) immunotherapy called IMNN-001 in patients with advanced ovarian cancer. 30 July 2024
Latest In Brief for Merck KGaA
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Latest Relevant Ones To Watch News
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
8 October 2024
24 September 2024
9 September 2024
5 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze